SLC5A2 and type 2 diabetes mellitus: In addition, a recent meta-analysis showed that SGLT2 inhibitors may notonly reduce uric acid levels, but also potentially prevent gout-related adverseevents in people with T2DM (hazard ratio (HR) 0.70, 95% CI: 0.59 to 0.84, p < 0.001,I2 = 84%) [60].